Tag: Trastuzumab

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Trastuzumab

Trastuzumab Deruxtecan Shows Promise in HER2+ BC with Brain Metastases

Added to Collection on: 2024-09-15 18:39:34

Tags for this article:

Orphan drugs
Cancer treatments
Antineoplastic drugs
Breast cancer
Antibody-drug conjugates
Tucatinib
Nancy Lin
Brain metastasis
Trastuzumab deruxtecan
Trastuzumab
HER2
Metastatic breast cancer
Cristina Saura Manich
Capecitabine

Click the tags to see associated articles and topics

View Article Details
September 2024 FDA Roundup: Key Decisions Drive Oncology Forward

Added to Collection on: 2024-10-02 21:06:41

Tags for this article:

Orphan drugs
Antineoplastic drugs
Cancer immunotherapy
Immunology
Pembrolizumab
Atezolizumab
Regenerative Medicine Advanced Therapy
Trastuzumab
Nivolumab
Amgen
Adobe

Click the tags to see associated articles and topics

View Article Details
Long-Term Data Add to Prognostic Value of TILs in Treatment De-Escalation in Early HER2+ ...

Added to Collection on: 2024-10-04 18:05:48

Tags for this article:

Oncology
Biomarkers
Breast cancer
TILS
Tumor-infiltrating lymphocytes
Cancer staging
HER2
Cancer biomarker
Prognosis marker
Trastuzumab

Click the tags to see associated articles and topics

View Article Details
Tweaks in drug formulations to extend copyrights is a public health challenge

Added to Collection on: 2024-10-28 06:07:02

Tags for this article:

Patent law
Specialty drugs
Pharmaceutical industry
Evergreening
Biosimilar
Biopharmaceutical
Novartis
Trastuzumab
Chemical patent
Patent
Adalimumab
United States
India

Click the tags to see associated articles and topics

View Article Details
Biosimilars Market to grow by USD 54.35 billion (2024-2028), cost advantage over biologics ...

Added to Collection on: 2024-11-15 22:18:43

Tags for this article:

Specialty drugs
Biopharmaceuticals
Biosimilar
Biotechnology
Trastuzumab
Pharmaceutical industry in India
Novartis
Biogen
Viatris
Sarfaraz K. Niazi
Association for Accessible Medicines

Click the tags to see associated articles and topics

View Article Details
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer | pharmaphorum

Added to Collection on: 2025-01-19 02:36:53

Tags for this article:

Antineoplastic drugs
Orphan drugs
Immunology
Breast cancer
Lung cancer
Antibody-drug conjugate
Durvalumab
Trastuzumab deruxtecan
Non-small-cell lung cancer
HER2
Triple-negative breast cancer
Trastuzumab
AstraZeneca
Daiichi Sankyo

Click the tags to see associated articles and topics

View Article Details
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor ...

Added to Collection on: 2025-01-23 20:09:05

Tags for this article:

Breast cancer
Cancer treatments
HER2
Oncogenes
Tumor microenvironment
CAR T cell
Adoptive cell transfer
Trastuzumab
EXUMA Biotech Corp.

Click the tags to see associated articles and topics

View Article Details
Boost to Enhertu's prospects as FDA clears Roche diagnostic - pharmaphorum

Added to Collection on: 2025-02-02 21:10:02

Tags for this article:

Orphan drugs
Antibody-drug conjugates
Immunology
Antineoplastic drugs
Cancer treatments
Trastuzumab deruxtecan
HER2
Trastuzumab
Antibody-drug conjugate
Breast cancer
Pertuzumab
Dalpiciclib
Roche Diagnostics
Daiichi Sankyo

Click the tags to see associated articles and topics

View Article Details
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 ...

Added to Collection on: 2025-02-13 21:19:16

Tags for this article:

Breast cancer
Cancer treatments
Immunology
Chloroarenes
Neratinib
Nitriles
Trastuzumab
HER2
Puma Biotechnology
Trastuzumab emtansine
Xavier Pivot

Click the tags to see associated articles and topics

View Article Details
Puma Biotechnology Q4 2024 Earnings Call Scheduled for February 27 - Stock Titan

Added to Collection on: 2025-02-13 21:18:00

Tags for this article:

Chloroarenes
Cancer treatments
Neratinib
Nitriles
Quinolines
Puma Biotechnology
HER2
Puma
Trastuzumab
Alisertib
Breast cancer

Click the tags to see associated articles and topics

View Article Details